Literature DB >> 9712016

Age and causes of death in adult-onset myotonic dystrophy.

C E de Die-Smulders1, C J Höweler, C Thijs, J F Mirandolle, H B Anten, H J Smeets, K E Chandler, J P Geraedts.   

Abstract

Myotonic dystrophy is a relatively common type of muscular dystrophy, associated with a variety of systemic complications. Long term follow-up is difficult because of the slow progression. The objective of this study was to determine survival, age at death and causes of death in patients with the adult-onset type of myotonic dystrophy. A register of myotonic dystrophy patients was set up in Southern Limburg (the Netherlands), using data longitudinally collected over a 47-year period (1950-97). Survival for 180 patients (from the register) with adult-onset type myotonic dystrophy was established by the Kaplan-Meier method. The median survival was 60 years for males and 59 years for females. Survival of the patients was also estimated from the age of 15 years to the ages of 25, 45 and 65 years and compared with the expected survival of age- and sex-matched birth cohorts from the normal Dutch population. The observed survival to the ages of 25, 45 and 65 years was 99%, 88% and 18% compared with an expected survival of 99%, 95% and 78%, respectively. Thus, survival to the age of 65 in patients with adult-onset myotonic dystrophy is markedly reduced. A weak positive correlation between the CTG repeat length and younger age at death was found in the 13 patients studied (r = 0.50, P = 0.08). The cause of death could be determined in 70 of the 83 deceased patients. Pneumonia and cardiac arrhythmias were the most frequent primary causes of death, each occurring in approximately 30%, which was far more than expected for the general Dutch population. In addition, we assessed mobility in the years before death in a subgroup of 18 patients, as a reflection of the long-term physical handicap in myotonic dystrophy patients. Half of the patients studied were either partially or totally wheelchair-bound shortly before their death.

Entities:  

Mesh:

Year:  1998        PMID: 9712016     DOI: 10.1093/brain/121.8.1557

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  52 in total

1.  Cancer risk among patients with myotonic muscular dystrophy.

Authors:  Shahinaz M Gadalla; Marie Lund; Ruth M Pfeiffer; Sanne Gørtz; Christine M Mueller; Richard T Moxley; Sigurdur Y Kristinsson; Magnus Björkholm; Fatma M Shebl; James E Hilbert; Ola Landgren; Jan Wohlfahrt; Mads Melbye; Mark H Greene
Journal:  JAMA       Date:  2011-12-14       Impact factor: 56.272

2.  Towards an integrative approach to the management of myotonic dystrophy type 1.

Authors:  Cynthia Gagnon; Luc Noreau; Richard T Moxley; Luc Laberge; Stéphane Jean; Louis Richer; Michel Perron; Suzanne Veillette; Jean Mathieu
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-04-20       Impact factor: 10.154

3.  Development and Validation of a New Scoring System to Predict Survival in Patients With Myotonic Dystrophy Type 1.

Authors:  Karim Wahbi; Raphaël Porcher; Pascal Laforêt; Abdallah Fayssoil; Henri Marc Bécane; Arnaud Lazarus; Maximilien Sochala; Tanya Stojkovic; Anthony Béhin; Sarah Leonard-Louis; Pauline Arnaud; Denis Furling; Vincent Probst; Dominique Babuty; Sybille Pellieux; Nicolas Clementy; Guillaume Bassez; Yann Péréon; Bruno Eymard; Denis Duboc
Journal:  JAMA Neurol       Date:  2018-05-01       Impact factor: 18.302

Review 4.  Oropharyngeal dysphagia in myotonic dystrophy type 1: a systematic review.

Authors:  Walmari Pilz; Laura W J Baijens; Bernd Kremer
Journal:  Dysphagia       Date:  2014-01-24       Impact factor: 3.438

Review 5.  Therapeutics development in myotonic dystrophy type 1.

Authors:  Erin Pennock Foff; Mani S Mahadevan
Journal:  Muscle Nerve       Date:  2011-05-23       Impact factor: 3.217

6.  Pigmentation phenotype, photosensitivity and skin neoplasms in patients with myotonic dystrophy.

Authors:  S M Gadalla; J E Hilbert; W B Martens; S Givens; R T Moxley; M H Greene
Journal:  Eur J Neurol       Date:  2017-03-20       Impact factor: 6.089

Review 7.  Myotonic dystrophy.

Authors:  Charles A Thornton
Journal:  Neurol Clin       Date:  2014-06-06       Impact factor: 3.806

8.  Heart rate variability declines with increasing age and CTG repeat length in patients with myotonic dystrophy type 1.

Authors:  Bradley A Hardin; Miriam R Lowe; Deepak Bhakta; William J Groh
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-07       Impact factor: 1.468

9.  Dmpk gene deletion or antisense knockdown does not compromise cardiac or skeletal muscle function in mice.

Authors:  Samuel T Carrell; Ellie M Carrell; David Auerbach; Sanjay K Pandey; C Frank Bennett; Robert T Dirksen; Charles A Thornton
Journal:  Hum Mol Genet       Date:  2016-08-13       Impact factor: 6.150

10.  Usefulness of clinical and electrocardiographic data for predicting adverse cardiac events in patients with myotonic dystrophy.

Authors:  Robert Breton; Jean Mathieu
Journal:  Can J Cardiol       Date:  2009-02       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.